{
    "clinical_study": {
        "@rank": "83872", 
        "arm_group": [
            {
                "arm_group_label": "Axitinib + Sandostatin LAR", 
                "arm_group_type": "Experimental", 
                "description": "Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days"
            }, 
            {
                "arm_group_label": "Placebo + Sandostatin LAR", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo BID + Sandostatin LAR 30mg/28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Axitinib prolongs progression-free survival of\n      patients with advanced well differentiated neuroendocrine carcinomas of non-pancreatic\n      origin compared to placebo."
        }, 
        "brief_title": "Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Well-differentiated Non-pancreatic Neuroendocrine Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Neuroendocrine"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed well or moderately differentiated neuroendocrine carcinoma\n             (grade I and II WHO 2010)of non-pancreatic origin\n\n          2. Ki-67<20%\n\n          3. Metastatic or locally advanced disease (clinically or radiologically confirmed) not\n             amenable to treatment with curative intent\n\n          4. Progressive disease documented in the prior 12 months (RECIST criteria)\n\n          5. Measurable disease\n\n          6. Prior treatment with somatostatin analogues permitted\n\n          7. Prior interferon therapy allowed\n\n          8. One prior systemic chemotherapy allowed\n\n          9. No prior VEGF- or VEGFR-targeted therapy allowed\n\n         10. Adequate organ function as defined by the following criteria:\n\n               -  absolute neutrophil count (ANC) \u22651500 cells/mm3;\n\n               -  platelets \u226575,000 cells/mm3;\n\n               -  hemoglobin \u22659.0 g/dL;\n\n               -  AST and ALT \u22642.5 x upper limit of normal (ULN), unless there are liver\n                  metastases in which case AST and ALT \u22645.0 x ULN;\n\n               -  total bilirubin \u22641.5 x ULN;\n\n               -  serum creatinine \u22641.5 x ULN or calculated creatinine clearance \u226560 mL/min;\n\n               -  urinary protein <2+ by urine dipstick. If dipstick is \u22652+ then a 24-hour urine\n                  collection can be done and the patient may enter only if urinary protein is <2 g\n                  per 24 hours.\n\n         11. Male or female, age \u226518 years.\n\n         12. ECOG performance status of 0-2.\n\n         13. Life expectancy of \u226512 weeks.\n\n         14. At least 4 weeks since the end of prior systemic treatment, radiotherapy, or surgical\n             procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 3.0\n             grade \u22641 or back to baseline except for alopecia or hypothyroidism.\n\n         15. No evidence of preexisting uncontrolled hypertension as documented by 2 baseline\n             blood pressure readings taken at least 1 hour apart. The baseline systolic blood\n             pressure readings must be \u2264150 mm Hg, and the baseline diastolic blood pressure\n             readings must be \u226490 mm Hg. Patients whose hypertension is controlled by\n             antihypertensive therapies are eligible.\n\n         16. Women of childbearing potential must have a negative serum or urine pregnancy test\n             within 3 days prior to treatment.\n\n         17. Signed and dated informed consent document indicating that the patient (or legally\n             acceptable representative) has been informed of all pertinent aspects of the trial\n             prior to enrollment.\n\n         18. Willingness and ability to comply with scheduled visits, treatment plans and study\n             procedures.\n\n        Exclusion Criteria:\n\n          1. The following endocrine tumor types may not be included: paraganglioma, adrenal,\n             thyroid, parathyroid or pituitary endocrine tumors.\n\n          2. Major surgery in <4 weeks or radiation therapy <2 weeks prior to starting the study\n             treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted,\n             provided there is at least one measurable lesion that has not been irradiated.\n\n          3. Gastrointestinal abnormalities including:\n\n               -  inability to take oral medication;\n\n               -  requirement for intravenous alimentation;\n\n               -  prior surgical procedures affecting absorption including total gastric\n                  resection;\n\n               -  treatment for active peptic ulcer disease in the past 6 months;\n\n               -  active gastrointestinal bleeding, unrelated to cancer, as evidenced by\n                  hematemesis, hematochezia or melena in the past 3 months without evidence of\n                  resolution documented by endoscopy or colonoscopy;\n\n               -  malabsorption syndromes.\n\n          4. Current use or anticipated need for treatment with drugs that are known potent CYP3A4\n             inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,\n             erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir,\n             nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine)unless\n             they can be substituted with a different medication with minimal inhibition of\n             CYP3A4/5. The coadministration could reduce the plasmatic concentration of axitinib.\n\n          5. Current use or anticipated need for treatment with drugs that are known CYP3A4/5\n             inducers (ie, carbamazepine, dexamethasone, felbamate, phenobarbital, phenytoin,\n             amobarbital, nevirapine, primidone, rifabutin, rifampin, and St.John's wort)unless\n             they can be substituted with a different medication with minimal inhibition of\n             CYP3A4. The coadministration could reduce the plasmatic concentration of axitinib.\n\n          6. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose\n             anticoagulants for maintenance of patency of central venous access devise or\n             prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular\n             weight heparin is allowed.\n\n          7. Active seizure disorder or evidence of brain metastases, spinal cord compression, or\n             carcinomatous meningitis.\n\n          8. A serious uncontrolled medical disorder or active infection that would impair their\n             ability to receive study treatment.\n\n          9. Any of the following within the 12 months prior to study drug administration:\n\n             myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft,\n             symptomatic congestive heart failure, cerebrovascular accident or transient ischemic\n             attack and 6 months for deep vein thrombosis or pulmonary embolism.\n\n         10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome\n             (AIDS)-related illness.\n\n         11. History of a malignancy (other than renal cell cancer) except those treated with\n             curative intent for skin cancer (other than melanoma), in situ breast or in situ\n             cervical cancer, or those treated with curative intent for any other cancer with no\n             evidence of disease for 5 years.\n\n         12. Dementia or significantly altered mental status that would prohibit the understanding\n             or rendering of informed consent and compliance with the requirements of this\n             protocol.\n\n         13. Female patients who are pregnant or lactating, or men and women of reproductive\n             potential not willing or not able to employ an effective method of birth\n             control/contraception to prevent pregnancy during treatment and for 6 months after\n             discontinuing study treatment The definition of effective contraception should be in\n             agreement with local regulation and based on the judgment of the principal\n             investigator or a designated associate.\n\n         14. Other severe acute or chronic medical or psychiatric condition, or laboratory\n             abnormality that may increase the risk associated with study participation or study\n             drug administration, or may interfere with the interpretation of study results, and\n             in the judgment of the investigator would make the patient inappropriate for entry\n             into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744249", 
            "org_study_id": "AXI-IIG-02", 
            "secondary_id": "2011-001550-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Axitinib + Sandostatin LAR", 
                "description": "Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.", 
                "intervention_name": "Axitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Axitinib + Sandostatin LAR", 
                    "Placebo + Sandostatin LAR"
                ], 
                "description": "Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity", 
                "intervention_name": "Sandostatin LAR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + Sandostatin LAR", 
                "description": "orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "carcinoid tumor", 
            "axitinib"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias"
                    }, 
                    "name": "Hospital Central de Asturias"
                }, 
                "investigator": {
                    "last_name": "Paula Jim\u00e9nez Fonseca, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona"
                    }, 
                    "name": "Institut Catal\u00e0 d'Oncologia L'Hospitalet"
                }, 
                "investigator": {
                    "last_name": "Alexandre Teul\u00e9, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain"
                    }, 
                    "name": "Complejo Hospitalario Univ A Coru\u00f1a"
                }, 
                "investigator": [
                    {
                        "last_name": "Luis ant\u00f3n Aparicio, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mar\u00eda Quind\u00f3s, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari Vall d'Hebron"
                }, 
                "investigator": {
                    "last_name": "Jaume Capdevila, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Guillermo Crespo Herrero, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Burgos", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario de Burgos"
                }, 
                "investigator": {
                    "last_name": "Guillermo Crespo Herrero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Virgen de las Nieves"
                }, 
                "investigator": {
                    "last_name": "Encarnaci\u00f3n Gonz\u00e1lez Flores, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Beatriz Nieto Mangudo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leon", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital universitario de Leon"
                }, 
                "investigator": {
                    "last_name": "Beatriz Nieto Mangudo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }, 
                "investigator": {
                    "last_name": "Enrique Grande Pulido, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Daniel Castellano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednico San Carlos"
                }, 
                "investigator": {
                    "last_name": "Javier Sastre", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jesus Rodr\u00edguez Pascual, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Clara Campal"
                }, 
                "investigator": {
                    "last_name": "Jesus Rodr\u00edguez Pascual, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Univ La Paz"
                }, 
                "investigator": {
                    "last_name": "Jorge Barriuso, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Gregorio Mara\u00f1\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Pilar Garc\u00eda Alfonso, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Univ de Salamanca"
                }, 
                "investigator": {
                    "last_name": "Miguel Navarro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Sebastian", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital de Donostia"
                }, 
                "investigator": [
                    {
                        "last_name": "Adelaida La Casta, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Sara Ar\u00e9valo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Marqu\u00e9s de Valdecilla"
                }, 
                "investigator": {
                    "last_name": "Carlos L\u00f3pez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }, 
                "investigator": {
                    "last_name": "Roc\u00edo Garc\u00eda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "\u00c1ngel Segura, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital La Fe"
                }, 
                "investigator": {
                    "last_name": "\u00c1ngel Segura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Miguel Servet"
                }, 
                "investigator": {
                    "last_name": "Vicente Alonso, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Placebo in Patients With Progressive Advanced Well-differentiated Neuroendocrine Carcinomas of Non-pancreatic Origin", 
        "overall_contact": {
            "email": "rgcarbonero@hotmail.com", 
            "last_name": "Rocio Garcia-Carbonero, MD", 
            "phone": "0034 93 451 1724"
        }, 
        "overall_official": [
            {
                "affiliation": "Complejo Hospitalario Universitario A Coru\u00f1a", 
                "last_name": "Luis Ant\u00f3n Aparicio, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Central de Asturias", 
                "last_name": "Paula Jim\u00e9nez Fonseca, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Marques de Valdecilla", 
                "last_name": "Carlos L\u00f3pez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Miguel Servet", 
                "last_name": "Vicente Alonso Ordu\u00f1a, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital de Donostia", 
                "last_name": "Adelaida La Casta, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario de Salamanca", 
                "last_name": "Miguel Navarro, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Gregorio Mara\u00f1\u00f3n", 
                "last_name": "Pilar Garcia Alfonso, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario La Paz", 
                "last_name": "Jorge Barriuso, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital Virgen de las Nieves", 
                "last_name": "Encarnaci\u00f3n Gonz\u00e1lez Flores, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Virgen del Rocio", 
                "last_name": "Rocio Garcia Carbonero, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hospital Cl\u00ednico San Carlos", 
                "last_name": "Javier Sastre, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Ram\u00f3n y Cajal", 
                "last_name": "Enrique Grande, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital U 12 de Octubre", 
                "last_name": "Daniel Castellano, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Vall d'Hebron", 
                "last_name": "Jaume Capdevila, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ICO Hospitalet", 
                "last_name": "Alexandre Teul\u00e9 Vega, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Clara Campal", 
                "last_name": "Jesus Rodr\u00edguez Pascual, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario de Le\u00f3n", 
                "last_name": "Beatriz Nieto Mangudo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario de Burgos", 
                "last_name": "Guillermo Crespo Herrero, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital La Fe", 
                "last_name": "\u00c1ngel Segura, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "calculated from the date of random assignment until the date of first progressive disease or tumor-related death", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "until disease progression, end of treatment or minimum 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (RECIST criteria) and duration of response", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, end of treatment or minimum 6 months"
            }, 
            {
                "measure": "Biochemical response (5-OH-Indolacetic acid and chromogranin A)", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression, end of treatment or minimum 6 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Until death, last follow-up,  or minimum 6 months"
            }, 
            {
                "description": "All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)", 
                "measure": "Safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "Until disease progression, end of treatment or minimum 6 months"
            }, 
            {
                "description": "The following parameters will be measured: Circulating tumor cells, circulating endothelial cells, hypertension and other biomarkers of angiogenesis(in tumor and serum).\nPeripheral blood samples (9ml)  will be obtained before treatment, after 1 month since the start of treatment and after disease progression. If progression is not achieved, an additional sample will be collected after 6 months of treatment. The blood samples will be processed for mRNA extraction. Hypoxia dependant genes  and marker genes which transcription depends on the activation of VEGF,  will be analyzed using qPCR. The dynamic profile of those genes will then be analyzed in relation to the response to axitinib, evaluating their predictive value of response.\nParaffin-embedded tumor tissue will also be collected from all patients to investigate the prognostic value and predictive potential of the different intracellular pathways related to VEGFR, PDGFR and other signaling pathways.", 
                "measure": "Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or after 6 months of treatment"
            }
        ], 
        "source": "Grupo Espanol de Tumores Neuroendocrinos", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo Espanol de Tumores Neuroendocrinos", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}